Phase 2 study NCT04784897 status COMPLETE official
Post# of 72440
(Total Views: 611)
Posted On: 08/13/2021 10:30:08 AM
Phase 2 study NCT04784897 status COMPLETE official
Unique Protocol ID: IPI-BRIc-201
Brief Title: A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19
Official Title: A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19
Secondary IDs:
Open or close this module Study Status
Record Verification: August 2021
Overall Status: Completed. <————————————————
Study Start: February 22, 2021
Primary Completion: July 1, 2021 [Actual]
Study Completion: July 30, 2021 [Actual]
First Submitted: March 3, 2021
First Submitted that
Met QC Criteria: March 3, 2021
First Posted: March 5, 2021 [Actual]
Last Update Submitted that
Met QC Criteria: August 11, 2021
Last Update Posted: August 13, 2021 [Estimate]
Unique Protocol ID: IPI-BRIc-201
Brief Title: A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19
Official Title: A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19
Secondary IDs:
Open or close this module Study Status
Record Verification: August 2021
Overall Status: Completed. <————————————————
Study Start: February 22, 2021
Primary Completion: July 1, 2021 [Actual]
Study Completion: July 30, 2021 [Actual]
First Submitted: March 3, 2021
First Submitted that
Met QC Criteria: March 3, 2021
First Posted: March 5, 2021 [Actual]
Last Update Submitted that
Met QC Criteria: August 11, 2021
Last Update Posted: August 13, 2021 [Estimate]
(4)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Ronald A Phillips
Scroll down for more posts ▼